spacer
home > pmps > summer 2018 > connected health services and smart device solutions
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Connected Health Services and Smart Device Solutions

The market model for traditional pharmaceuticals, which is based on formulary positioning and prescriptions given by doctors, has been under pressure, giving rise to an end-user and consumer-driven approach. Additionally, changes in payment models have been linked to positive patient outcomes, otherwise known as ‘payment by results’.

For pharmaceuticals, the concept of patient centricity is a major trend, which – alongside more defined clinical/regulatory approaches, an increased number of biologic drugs, higher-drug specificity, and treatments linked to diagnostic data – is combining with a subsegmentation approach that concerns patients where drugs can be most effective. While efficacy and safety are still fundamental for gaining drug approval, also of importance is exploring and understanding the care journey provides valuable insight into the needs of stakeholders, as well as the basis for defining services that are essential for stakeholders and patients in subsegments. A service model that is dedicated to the drug will be able to meet individual and segment needs, including secondary disease measures, monitoring, and adherence and compliance services. Smooth interaction with stakeholders is critical for deriving value from this drug/ service differentiation. This change in the stakeholder/patient engagement equation evidences that bespoke connected health services are proving to be vital tools.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Print this page
Send to a friend
Privacy statement
News and Press Releases

RSSL introduces same-day mycoplasma testing service in UK

Reading Scientific Services Ltd (RSSL), a leading provider of scientific and technical solutions to the global biopharmaceutical, pharmaceutical, and biopharmaceutical sectors, has introduced the United Kingdom’s first same-day mycoplasma testing service for manufacturers of biologic medicines.
More info >>

White Papers

Orthogonal Approaches for the Analysis of Protein Sequence

Ludger Ltd

One of the most important classes of biopharmaceuticals is monoclonal antibodies. They are expressed from living cells, and are consequently subject to complex biochemical pathways. Not all of these routes are fully understood, and many are sensitive to the subtlest of environmental changes. Changes such as these can affect the final biopharmaceutical sequence, structure and post-translational modifications, not to mention any changes that may occur during further purification. This often means that the final product from one batch may be different from the last in another batch. Each batch is a complicated mix of similar molecules, and analysis of the degree of batch-to-batch variation is therefore very important to the establishment of the drug's safety for medicinal use and patient administration.
More info >>

 
Industry Events

Respiratory Drug Delivery (RDD®) Europe 2019

7-10 May 2019, Estoril Congress Center, Lisbon

Respiratory Drug Delivery (RDD®) Europe 2019 connects emerging and high-level scientists, academics, industrial and regulatory specialists, and clinicians. It is a must-attend conference for companies involved in research, development, testing or marketing of medicines, devices and services associated with pulmonary or nasal pharmaceutical products. This year, RDD Europe 2019 will be held in Estoril (Lisbon), Portugal, May 7-10, 2019, and, as in previous years is jointly organized by RDD Online and Aptar Pharma.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement